A high resolution gas chromatographic/mass spectrometric method for the determination of N-0923 in human and monkey plasma.
A method that combines gas chromatography and mass spectrometry (GC/MS) for the determination of N-0923 in human and monkey plasma is detailed. This novel drug holds promise for the treatment of Parkinson's disease. Clinical use of N-0923 will result both in low peak plasma concentrations and in a short half-life; consequently, a highly sensitive method will be required. Previous methods using high-performance liquid chromatography with electrochemical detection have given reliable data in high dose studies in animals to 0.3-1.0 ng/mL in plasma but are not considered adequate for studies at clinical levels in humans. The data in this paper will show that GC/MS can offer a new direction in the determination of N-0923 in human and monkey samples, with reliable data to 25 pg/mL in plasma. This method is presented as a novel approach to the determination of N-0923, and as a starting point for further development.
Zavitsanos
P A
PA
LAB-BioResearches Inc., Montreal, Quebec, Canada.
Siddiqui
W
W
Curtis
M
M
D000818:Animals; D015259:Dopamine Agents / Q000032:analysis* / Q000097:blood; D008401:Gas Chromatography-Mass Spectrometry / Q000379:methods*; D000882:Haplorhini; D006801:Humans; D013764:Tetrahydronaphthalenes / Q000032:analysis* / Q000097:blood; D013876:Thiophenes / Q000032:analysis* / Q000097:blood
D015259:Dopamine Agents; D013764:Tetrahydronaphthalenes; D013876:Thiophenes; C047508:rotigotine